Milk thistle for the treatment of liver disease: a systematic review and meta-analysis (Q34994556)

5 August 2017

0 references

1 reference

title

Milk thistle for the treatment of liver disease: a systematic review and meta-analysis (English)

1 reference

5 August 2017

0 references

1 reference

1 reference

Bradly P Jacobs

1

1 reference

5 August 2017

Cathi Dennehy

2

1 reference

5 August 2017

Gilbert Ramirez

3

1 reference

5 August 2017

Jodi Sapp

4

1 reference

5 August 2017

Valerie A Lawrence

5

1 reference

5 August 2017

language of work or name

English

0 references

publication date

1 October 2002

1 reference

American Journal of Medicine

5 August 2017

1 reference

5 August 2017

113

1 reference

5 August 2017

6

1 reference

5 August 2017

506-515

1 reference

Advances in the treatment of chronic viral hepatitis

5 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901244-5

Hepatic disorders. Features and appropriate management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901244-5

The treatment of chronic viral hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901244-5

Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901244-5

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901244-5

Therapy of hepatitis C: patients with cirrhosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901244-5

Combination therapy for hepatitis C infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901244-5

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901244-5

Side effects of alpha interferon in chronic hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901244-5

Protective effect of the flavonoid silybin dihemisuccinate on the toxicity of phenylhydrazine on rat liver

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901244-5

Silybin dihemisuccinate protects against glutathione depletion and lipid peroxidation induced by acetaminophen on rat liver

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901244-5

Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901244-5

Prevention by silybin of phalloidin-induced acute hepatoxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901244-5

Silymarin protects against paracetamol-induced lipid peroxidation and liver damage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901244-5

Biochemical effect of antioxidants on lipids and liver function in experimentally-induced liver damage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901244-5

The effect of silymarin and gamma radiation on nucleic acids in rat organs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901244-5

Scavenging effect of silipide, a new silybin-phospholipid complex, on ethanol-derived free radicals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901244-5

Protection by silibinin against Amanita phalloides intoxication in beagles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901244-5

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901244-5

Aminotransferase levels and silymarin in de novo tacrine-treated patients with Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901244-5

Long-term (12 months) treatment with an anti-oxidant drug (silymarin) is effective on hyperinsulinemia, exogenous insulin need and malondialdehyde levels in cirrhotic diabetic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901244-5

Effect of silymarin on chemical, functional, and morphological alterations of the liver. A double-blind controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901244-5

Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901244-5

Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901244-5

Hepatotoxicity associated with herbal tablets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901244-5

Notizen: Silydianin und Silychristin, zwei isomere Silymarine aus Silybum marianum L. Gaertn. (Mariendistel) / Silydianin and Silychristin, two Isomeric Silymarins from Silybum marianum L. Gaertn. (milk thistle)

7 January 2021

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.1515/ZNB-1976-0630

Identifiers

DOI

10.1016/S0002-9343(02)01244-5

1 reference

5 August 2017

1 reference